Introduction

Measles is a serious disease that used to be very common in the world.

There are 2 vaccines that can prevent measles:

• The MMR vaccine protects children and adults from measles, mumps, and rubella
• The MMRV vaccine protects children from measles, mumps, rubella, and chickenpox

Why is vaccine important?

Measles is one of the most contagious diseases there is. If 1 person has it, 9 out of 10 people close to that person who are not immune (protected) will also get measles. And it can be dangerous — serious cases of measles can lead to brain damage and even death.

In recent years, measles outbreaks have increased in the United States and around the world in places like Europe, Africa, and South America. Outbreaks typically happen in areas where groups of people do not get vaccinated. Since measles is still common in other countries, people can get the disease when they travel -and spread it to people who are not vaccinated when they come home.

Getting vaccinated is the best way to prevent measles. And when enough people get vaccinated against measles, the entire community is less likely to get it. So, when you and your family get vaccinated, you help keep yourselves and your community healthy.

Who needs vaccine?

Children need 2 doses of the vaccine at the following ages:

• 12 through 15 months for the first dose
• 4 through 6 years for the second dose (or sooner if it is 28 days after the first dose)

Adults: If you did not get the measles vaccine as child, you may need to get it as an adult.

Side-effects

Side effects are usually mild and go away in a few days. They may include:

• Fever
• A mild rash
• Swollen glands in the cheeks or neck
• Less common side effects of the measles vaccine include:
• Pain or stiffness in the joints, usually in women (up to 1 person out of 4)
• Seizures (sudden, unusual movements or behavior) from having a high fever (about 1 out of every 3,000 doses)
• Temporary (short-term) low platelet count (about 1 out of every 30,000 doses)

Conclusion

Our Journal is planning to release a year end special issue has announced almost 50% discount on article publication charges to celebrate its journey for publishing articles within the short time.

 A standard editorial manager system is utilized for manuscript submission, review, editorial processing and tracking which can be securely accessed by the authors, reviewers and editors for monitoring and tracking the article processing.

Manuscripts can be forwarded to the Editorial Office at autoimmunedis@eclinicalsci.com

How we work:

• After submission, an acknowledgement with manuscript number is sent to the corresponding author within 7 working days.
• A 21 day window time frame is allotted for peer-review process wherein multiple experts are contacted.
• Author proof is generated within 7 working days after the acceptance decision.

Media Contact:
John Kimberly
Editorial Manager
Journal of Vaccines & Vaccination
Email: jvv@scholarlypub.com